Medtronic received information that following the implant of this 31mm mitral bioprosthetic valve, the valve was reported to be placed in a good position.When the holder was disengaged, the valve seemed to be working appropriately.After the surgeon started tying off the sutures and testing the valve, one leaflet appeared to not be moving correctly.There was evidence of severe regurgitation and the leaflets were not coaptating properly.The valve was explanted and successfully replaced with a 29mm bioprosthetic valve of the same model.No additional adverse patient effects were reported.
|
Product analysis: upon receipt at medtronic's quality laboratory, visual examination revealed minor damage on the sewing ring, righ cusp, and left cusp which was likely caused during the explant process.All leaflets were flexible in a semi-relaxed position, which is a standard finding for this valve.Hydrodynamic pulse duplication testing with high speed video observation showed normal, full opening and closing leaflet motion with no evidence of leakage at all flow rates/cardiac outputs.Flow through the valve was documented using echocardiography, digital high speed imaging, and flow meter assessment, and was deemed acceptable.All commissures were intact.Conclusion: the device history record was reviewed and showed that this product met all manufacturing specifications for product released for distribution.No issues were identified that would have impacted this event.The cause of the regurgitation could not be confirmed.H6: coding updated.Medtronic is submitting this report to comply with fda reporting regulations under 21 cfr parts 4 and 803.This report is based upon information obtained by medtronic, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Medtronic has made reasonable efforts to obtain more complete information and has provided as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.In particular, this report does not constitute an admission by anyone that the product described in this report has any ¿defects¿ or has ¿malfunctioned¿.These words are included in the fda 3500a form and are fixed items for selection created by the fda to categorize the type of event solely for the purpose of regulatory reporting.Medtronic objects to the use of these words and others like them because of the lack of definition and the connotations implied by these terms.This statement should be included with any information or report disclosed to the public under the freedom of information act.
|